CStone Pharmaceuticals has signed a strategic commercialization partnership with SteinCares, a pharmaceutical company with over 40 years of experience and a strong presence in Latin America.

As part of this collaboration, SteinCares will be responsible for the regulatory affairs and commercialization activities of sugemalimab in these regions. CStone will supply sugemalimab and will receive upfront, regulatory, and commercial milestone payments as well as revenue from product supply.

Under this agreement, SteinCares will gain the commercialization rights for sugemalimab in 10 LATAM countries, including Brazil, Argentina, Mexico, Chile, Colombia, Costa Rica, Panama, Peru, Guatemala and Ecuador.

Dr. Jason Yang, CEO, President of R&D and Executive Director at CStone, stated, "Following our successful market entries in Central and Eastern Europe, Switzerland, as well as the Middle East and Africa, we are excited to announce another key milestone in the global expansion of sugemalimab. As the first anti-PD-L1 monoclonal antibody approved in both the EU and UK for first-line, all-comer, Stage IV non-small cell lung cancer (NSCLC), sugemalimab is well-positioned for success in Latin America. SteinCares' extensive distribution network and deep marketing expertise will significantly enhance sugemalimab's reach. We are also actively discussing with international partners in Western Europe, Southeast Asia, and Canada, while advancing regulatory submissions for additional indications of sugemalimab. We are confident that these efforts will further unlock the therapeutic and commercial potential of sugemalimab, ultimately benefiting patients worldwide."

Mitchell Waserstein, CEO of SteinCares, added, "This agreement with CStone represents a significant step forward in our mission to create healthcare opportunities for patients in LATAM. At SteinCares, we are committed to providing more Latin Americans with greater access to safe, innovative, and affordable therapies. With our extensive experience and established sales network across the region, we are confident in our ability to successfully commercialize sugemalimab in LATAM and make a meaningful impact on patients' health and well-being."